Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 7 of 33 for:    gi dynamics

Study for Pre-Surgical Weight Loss in Type II Diabetes Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GI Dynamics
ClinicalTrials.gov Identifier:
NCT00791128
First received: November 12, 2008
Last updated: November 1, 2016
Last verified: March 2016
  Purpose
The purpose of this study is to determine whether the GI Sleeve is safe and effective in treating Type II diabetes patients

Condition Intervention Phase
Type 2 Diabetes
Device: GI Sleeve
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Single-Center, Prospective, Open Label Study of Safety and Efficacy, of the GI Sleeve for Pre-Surgical Weight Loss, in Type II Diabetes Patients

Resource links provided by NLM:


Further study details as provided by GI Dynamics:

Primary Outcome Measures:
  • % of Excess Weight Loss [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Improvement in Type II Diabetes (Changes in HbA1c) [ Time Frame: 12 months ]

Enrollment: 22
Study Start Date: October 2008
Study Completion Date: December 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GI Sleeve
40 patients will be implanted with the GI Sleeve for up to 6 months.
Device: GI Sleeve
Medical device placed endoscopically in the duodenum
Other Name: GI Endobarrier

Detailed Description:
Patients with obesity are at significantly greater risk of developing complications such as pulmonary dysfunction, diabetes, hypertension, and other co-morbid risks. NIH panel recommendations state that even a 10% short-weight loss would greatly reduce these risks. GI Dynamics' GI Sleeve represents a viable alternative to other short-term pre-surgical weight loss methods. GI Sleeve is a device that can be implanted and removed through minimal invasive endoscopic techniques. This endoscopic procedure brings potential benefits to patients in that it is minimally invasive, efficacious, and allows patients to recover faster with less morbidity and mortality.
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 to 65
  • BMI 40 to 60
  • Type II Diabetes
  • Candidates for bariatric surgery

Exclusion Criteria:

Patients with

  • hepatitis B or C
  • GERD
  • HIV Positive diagnosis
  • pancreatitis
  • conditions of gastrointestinal tract, such as ulcers or Crohn's
  • an infection or who are H. Pylori positive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00791128

Locations
Brazil
Dr. Eduardo Guimaraes Hourneauz de Moura
Sao Paulo, SP, Brazil, 05493900
Sponsors and Collaborators
GI Dynamics
Investigators
Principal Investigator: Eduardo Guimaraes Hourneaux de Moura, MD Hospital das Clinicas, Sao Paulo
  More Information

Responsible Party: GI Dynamics
ClinicalTrials.gov Identifier: NCT00791128     History of Changes
Other Study ID Numbers: 06-6
Study First Received: November 12, 2008
Results First Received: November 1, 2016
Last Updated: November 1, 2016
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by GI Dynamics:
Type 2 Diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Weight Loss
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Body Weight Changes
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on April 28, 2017